[go: up one dir, main page]

DE60234193D1 - Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen - Google Patents

Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen

Info

Publication number
DE60234193D1
DE60234193D1 DE60234193T DE60234193T DE60234193D1 DE 60234193 D1 DE60234193 D1 DE 60234193D1 DE 60234193 T DE60234193 T DE 60234193T DE 60234193 T DE60234193 T DE 60234193T DE 60234193 D1 DE60234193 D1 DE 60234193D1
Authority
DE
Germany
Prior art keywords
geneva
bindings
disulphide
constructed
factor viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234193T
Other languages
English (en)
Inventor
John H Griffin
Andrew J Gale
Elizabeth D Getzoff
Jean-Luc Pellequer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE60234193D1 publication Critical patent/DE60234193D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60234193T 2001-06-14 2002-06-14 Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen Expired - Lifetime DE60234193D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29857801P 2001-06-14 2001-06-14
PCT/US2002/019017 WO2002103024A2 (en) 2001-06-14 2002-06-14 Stabilized proteins with engineered disulfide bonds

Publications (1)

Publication Number Publication Date
DE60234193D1 true DE60234193D1 (de) 2009-12-10

Family

ID=23151124

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234193T Expired - Lifetime DE60234193D1 (de) 2001-06-14 2002-06-14 Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen

Country Status (8)

Country Link
US (2) US7205278B2 (de)
EP (2) EP1421539B1 (de)
JP (2) JP4361786B2 (de)
AU (1) AU2002310438B2 (de)
CA (1) CA2450732A1 (de)
DE (1) DE60234193D1 (de)
ES (1) ES2331909T3 (de)
WO (1) WO2002103024A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234193D1 (de) * 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
EP1502921A1 (de) * 2003-07-29 2005-02-02 ZLB Behring GmbH Rekombinanter mutierter menschlicher Factor VIII (FVIII) mit verbesserter Stabilität
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
US20060019893A1 (en) * 2004-07-02 2006-01-26 Genentech, Inc. Factor VIIa variants
CN107082806A (zh) 2004-11-12 2017-08-22 拜尔健康护理有限责任公司 Fviii的位点定向修饰
JP2008537680A (ja) * 2005-04-14 2008-09-25 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 安定性の増大された改変型凝固第ｖｉｉｉ因子およびその誘導体
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
WO2008059041A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
KR101542752B1 (ko) 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
US8183345B2 (en) 2007-11-01 2012-05-22 University Of Rochester Recombinant factor VIII having reduced inactivation by activated protein C
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
ES2542202T3 (es) * 2009-01-22 2015-08-03 Novo Nordisk Health Care Ag Compuestos de hormonas de crecimiento estables
BR112012011464A2 (pt) * 2009-10-30 2015-09-15 Agres Ltd proteínas encapsuladas de óleo modificadas e seu uso
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
CN106139158B (zh) 2010-01-22 2024-06-21 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
CN102971006A (zh) * 2010-07-15 2013-03-13 诺沃—诺迪斯克有限公司 稳定的因子viii变体
JP2013533264A (ja) * 2010-07-22 2013-08-22 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモンコンジュゲート
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
BR112015022730A2 (pt) * 2013-03-15 2017-10-31 Bayer Healthcare Llc formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
WO2015066700A2 (en) 2013-11-04 2015-05-07 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
BR112017018468A2 (pt) 2015-03-06 2018-04-17 Csl Behring Recombinant Facility Ag fator de von willebrand modificado com meia-vida aumentada
MX2017014872A (es) 2015-05-22 2018-07-06 Csl Behring Recombinant Facility Ag Metodos para preparar factor de von willebrand modificado.
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CN104974228B (zh) * 2015-06-15 2017-10-17 四川合泰新光生物科技有限公司 一种小分子多肽zy4及其应用
EP3400238B1 (de) 2016-01-07 2021-05-19 CSL Behring Lengnau AG Mutierter von-willebrand-faktor
CN108472338B (zh) 2016-01-07 2022-12-30 康诺贝林伦瑙有限公司 突变的截短的von Willebrand因子
ES2869339T3 (es) 2016-11-11 2021-10-25 CSL Behring Lengnau AG Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia
EP3538134B1 (de) 2016-11-11 2021-12-29 CSL Behring Lengnau AG Verkürzte von-willebrand-faktor-polypeptide zur extravaskulären verabreichung bei der behandlung oder prophylaxe einer blutgerinnungsstörung
EP3781682A1 (de) 2018-04-19 2021-02-24 Stichting VU Proteinmakrocyclisierung
EP3810647A4 (de) * 2018-04-26 2022-08-17 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen zur behandlung von hämophilie

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) * 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0218712B1 (de) 1985-04-12 1992-02-26 Genetics Institute, Inc. Neue prokoagulierungsproteine
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US4852871A (en) * 1988-12-02 1989-08-01 John Perko Hand exercise device
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5610137A (en) * 1990-12-20 1997-03-11 The Uab Research Foundation Transgenic, cross-linked hemoglobin
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5114148A (en) * 1991-07-09 1992-05-19 Liu Ming Zen Puzzle device
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5543149A (en) * 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU743616B2 (en) 1997-02-07 2002-01-31 Merck & Co., Inc. Synthetic HIV gag genes
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DE60234193D1 (de) * 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen

Also Published As

Publication number Publication date
US20070276128A1 (en) 2007-11-29
CA2450732A1 (en) 2002-12-27
JP2005500831A (ja) 2005-01-13
EP1421539A2 (de) 2004-05-26
AU2002310438B2 (en) 2008-05-01
WO2002103024A3 (en) 2004-03-18
US20030125232A1 (en) 2003-07-03
EP2110385A8 (de) 2010-06-02
JP4361786B2 (ja) 2009-11-11
EP2110385A1 (de) 2009-10-21
US7205278B2 (en) 2007-04-17
EP1421539B1 (de) 2009-10-28
EP1421539A4 (de) 2005-11-09
ES2331909T3 (es) 2010-01-20
JP2008271975A (ja) 2008-11-13
WO2002103024A2 (en) 2002-12-27
US7928199B2 (en) 2011-04-19

Similar Documents

Publication Publication Date Title
DE60234193D1 (de) Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
DE60224791D1 (de) Gewindeverbindung
DK1421841T3 (da) Mejetærsker
FI20010694A0 (fi) Implantti
DE60136981D1 (de) Arthropoden Defensine
DE60213194D1 (de) Haltenadel mit flügel
ATE286478T1 (de) Verschlusskappe
DE60218081D1 (de) Markierungsteilchen
DE50212845D1 (de) Kunstharzpalette
DE50212108D1 (de) Substituierte fluoralkoxyphenylsulfonylharnstoffe
GB2376865B (en) Birdhouse with deployable fledging board
IS7330A (is) Lítill hokkí völlur
NO20020922D0 (no) Etikett
DE10111783B4 (de) Einspritzdüse
DE60223732D1 (de) Füllminenstift
HK1043912A2 (en) Huqin with added strings
DE60134712D1 (de) Regulierventil
DE60238850D1 (de) Rattenmodell mit regucalcin-überexpression
DE50203426D1 (de) Steuerknüppel
ATE296652T1 (de) Spritze
ATE303835T1 (de) Spritze
ES1049379Y (es) Paraguas
UA5432S (uk) Пенал
FIU20010062U0 (fi) Kangaspuut
SE0100582D0 (sv) Point

Legal Events

Date Code Title Description
8364 No opposition during term of opposition